Biocon Limited (BOM: 532523)
India
· Delayed Price · Currency is INR 401.05
+8.35 (2.13%)
At close: Jan 20, 2025
Biocon Revenue
Biocon had revenue of 35.90B INR in the quarter ending September 30, 2024, with 3.70% growth. This brings the company's revenue in the last twelve months to 148.94B, up 9.52% year-over-year. In the fiscal year ending March 31, 2024, Biocon had annual revenue of 147.56B with 32.05% growth.
Revenue (ttm)
148.94B
Revenue Growth
+9.52%
P/S Ratio
n/a
Revenue / Employee
9.13M
Employees
16,315
Market Cap
467.41B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 147.56B | 35.82B | 32.05% |
| Mar 31, 2023 | 111.74B | 29.90B | 36.54% |
| Mar 31, 2022 | 81.84B | 10.41B | 14.57% |
| Mar 31, 2021 | 71.43B | 8.43B | 13.37% |
| Mar 31, 2020 | 63.01B | 7.86B | 14.26% |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
| Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Reliance Industries | 9,398.38B |
| Tata Consultancy Services | 2,520.82B |
| HDFC Bank | 2,761.06B |
| Bharti Airtel | 1,554.78B |
| ICICI Bank | 1,638.51B |
| Infosys | 1,635.60B |
| State Bank of India | 3,360.28B |
| ITC Limited | 751.35B |
Biocon News
- 5 days ago - CCI penalises investment manager of Goldman Sachs AIF for failing to notify Biocon deal - The Times of India
- 5 days ago - Stock Market Update, January 16: BSE and Biocon hit new 52-week highs today - Business Upturn
- 5 days ago - Pharma sector stocks: Biocon (+3.10%), Aurobindo Pharma (+0.48%), Divis Labs (+0.39%) rise; Mankind Pharma (-1.43%) leads losers - Business Upturn
- 7 days ago - Pharma Stocks Today: Biocon surges 4.41%, Mankind Pharma up 1.85%; Glaxo and Abbott India decline - Business Upturn
- 7 days ago - Biocon shares surge nearly 4% as HSBC upgrades to ‘Buy’ - Business Upturn
- 7 days ago - HSBC upgrades Biocon to ‘Buy’, raises target price to ₹430 - Business Upturn
- 8 days ago - Biocon shares surge 4% today; Motilal Oswal upgrades stock to Buy - Business Upturn
- 8 days ago - Pharma stocks: Biocon up 3.84% on US FDA nod for Malaysia unit; Divi’s Lab gains 0.61%, Mankind Pharma slips 3.75%, GlaxoSmithKline drops 2.42% - Business Upturn